Peptide Regulatory Submission Requirements

Regulatory submission for peptide drugs requires comprehensive Chemistry, Manufacturing, and Controls (CMC) data, nonclinical studies, and clinical evidence. Peptides occupy a unique regulatory position between small molecules and biologics, with specific considerations for synthesis, characterization, and quality control.

Regulatory Pathways

US FDA Pathways

Pathway	Application	Timeline	Requirements
IND → NDA/BLA	New peptide drug	8–12 years	Full CMC, nonclinical, clinical
505(b)(2)	Modified peptide (reference listed drug)	3–5 years	Modified CMC, limited clinical
505(j)	Generic peptide (if applicable)	3–5 years	Bioequivalence, CMC
Orphan Drug	Rare disease peptide	6–8 years	Orphan designation, Phase III
Fast Track	Serious condition peptide	6–8 years	Accelerated development
Breakthrough	Superior existing therapy	5–7 years	Expedited review

EU Pathways

Pathway	Application	Timeline	Requirements
Centralized Procedure	Novel peptide	8–12 years	Full dossier (CTD)
Decentralized Procedure	National peptide	6–10 years	National + mutual recognition
Orphan designation	Rare disease	6–8 years	Orphan designation
Conditional MA	Serious/urgent need	6–8 years	Conditional approval

International Pathways

Region	Agency	Pathway	Key Requirements
Japan	PMDA	Standard	CT, J-CTD
China	NMPA	Standard	CTD, Chinese language
Australia	TGA	Standard	AU-CTD
Canada	Health Canada	Standard	CTD, bilingual
India	CDSCO	Standard	CT, CTD
Brazil	ANVISA	Standard	CTD, Portuguese

Common Technical Document (CTD)

CTD Module Structure

Module	Contents	Peptide-Specific Considerations
1	Administrative information	Regional requirements
2	Overviews and summaries	Quality overall summary
3	Quality (CMC)	Detailed SPPS, purification, characterization
4	Nonclinical reports	In vitro, in vivo, toxicology
5	Clinical reports	PK, efficacy, safety

Module 3: Quality (CMC) Structure

Section	Contents	Peptide-Specific
3.2.S.1	General information	Peptide class, nomenclature
3.2.S.2	Manufacture	SPPS process, cleavage, purification
3.2.S.3	Characterization	Structure, sequence, impurities
3.2.S.4	Control of drug substance	Specifications, methods
3.2.S.5	Reference standards	Primary, secondary, working
3.2.S.6	Container closure	Vial, stopper, seal
3.2.S.7	Stability	Long-term, accelerated, stress

CMC Requirements for Peptides

S.1: General Information

Item	Requirement	Example
INN	International nonproprietary name	Semaglutide
Chemical name	IUPAC or common	Human GLP-1 analogue
Amino acid sequence	Complete sequence with modifications	Ac-8-Aib-GLP-1(7-37)
Molecular formula	With modifications	C₁₈₇H₂₉₁N₄₅O₅₉
Molecular weight	Average and monoisotopic	4113.5 Da
Structural formula	2D or 3D representation	Peptide structure
Physical form	Lyophilized powder, solution	White to off-white powder
Solubility	Aqueous and organic	Freely soluble in water
Polymorphism	If applicable	Amorphous
CAS number	Registry	910463-68-2

S.2: Manufacture

Manufacturing Process Description

Section	Contents
Synthetic route	SPPS (Fmoc/tBu chemistry)
Starting materials	Amino acids, resin, reagents
Process description	Step-by-step with parameters
In-process controls	Kaiser test, HPLC monitoring
Cleavage/deprotection	TFA cocktail composition
Purification	RP-HPLC conditions
Lyophilization	Cycle parameters
Packaging	Container closure system

Starting Materials and Raw Materials

Material	Specification	Source	Regulatory Status
Fmoc-amino acids	≥98% purity	Qualified vendor	Drug master file
HBTU/HATU	≥99% purity	Qualified vendor	Drug master file
Piperidine	≥99% purity	Qualified vendor	Drug master file
TFA	≥99% purity	Qualified vendor	Drug master file
DMF	ACS grade	Qualified vendor	Drug master file
Resin	Specification	Qualified vendor	Drug master file
WFI	USP/EP grade	In-house	Qualification report

S.3: Characterization

Structural Characterization

Method	Purpose	Acceptance
ESI-MS or MALDI-MS	Molecular weight confirmation	Within 5 Da
Amino acid analysis	Composition verification	±10% of theoretical
Edman degradation	N-terminal sequence	Confirmed
Peptide mapping	Sequence confirmation	>95% coverage
CD spectroscopy	Secondary structure	Expected conformation
NMR (2D)	3D structure confirmation	Consistent with design
Chiral HPLC	D-amino acid content	≤1%
Disulfide bond analysis	Bond connectivity	Confirmed (if applicable)

Impurity Characterization

Impurity Type	Source	Method	Limit
Truncated peptides	Incomplete coupling	RP-HPLC	≤0.5% individual
Deleted peptides	Deprotection failure	RP-HPLC	≤0.5% individual
Oxidized peptides	Air oxidation	RP-HPLC	≤0.5% individual
D-amino acid peptides	Racemization	Chiral HPLC	≤0.5% individual
Aggregated peptides	Aggregation	SEC	≤1%
Residual TFA	Cleavage	¹⁹F NMR or IC	≤0.5% (w/w)
Residual solvents	Purification	GC-HS	Per ICH Q3C
Residual reagents	Synthesis	HPLC or IC	≤10 ppm
Metal catalysts	Synthesis	ICP-MS	Per Q3D

S.4: Control of Drug Substance

Specifications

Parameter	Method	Specification
Appearance	Visual	White to off-white powder
Identity (MS)	ESI-MS	[M+H]⁺ ±5 Da
Identity (AA)	AAA	Consistent with theoretical
Purity	RP-HPLC (UV)	≥95.0% (area)
Individual impurity	RP-HPLC	≤0.5%
Total impurities	RP-HPLC	≤2.0%
Residual TFA	IC or ¹⁹F NMR	≤0.5% (w/w)
Water content	Karl Fischer	≤3.0%
Peptide content	AAA or UV	85.0–115.0%
Counter ion	IC or titration	85.0–115.0% of label
Endotoxin	LAL/rFC	<5.0 EU/mg
Bioburden	USP <61>/<62>	<100 CFU/g
Residual solvents	GC-HS	Per ICH Q3C
Heavy metals	ICP-MS	Per ICH Q3D

Analytical Methods

Method	Validation Parameters	Reference
RP-HPLC (purity)	Specificity, linearity, accuracy, precision, range, robustness	ICH Q2
ESI-MS (identity)	Mass accuracy, resolution	Manufacturer specs
AAA (content)	Linearity, accuracy, precision	USP <1052>
Karl Fischer (water)	Accuracy, precision	USP <921>
LAL (endotoxin)	Sensitivity, interference	USP <85>
IC (counter ion)	Specificity, linearity, accuracy	USP <621>
GC-HS (residual solvents)	Specificity, linearity, accuracy	USP <467>

S.5: Reference Standards

Standard	Source	Characterization
Primary reference standard	Initial batch	Full characterization (S.3)
Secondary reference standard	Production batch	Compared to primary
Working reference standard	Production batch	Compared to secondary
In-house reference standard	Production batch	Used for routine testing

S.6: Container Closure System

Component	Material	Specification
Vial	Type I borosilicate glass	USP <660>
Stopper	Chlorobutyl or bromobutyl	USP <381>
Seal	Aluminum with flip-off cap	—
Secondary packaging	Carton with desiccant	Light protection
Labeling	Product, lot, expiry	Per regulatory

S.7: Stability

Study	Conditions	Duration	Timepoints
Long-term	25±2°C/60±5% RH	24 months	0, 3, 6, 9, 12, 18, 24 months
Accelerated	40±2°C/75±5% RH	6 months	0, 3, 6 months
Intermediate	30±2°C/65±5% RH	12 months	0, 6, 12 months
Photostability	1.2M lux·h + 200 W·h/m²	Per ICH Q1B	Before/after
In-use	Intended storage	Expected shelf life	Multiple

Nonclinical Requirements

Pharmacology

Study	Species	Duration	GLP
Primary pharmacology	Relevant species	Single/multiple dose	Yes
Secondary pharmacology	Relevant species	Multiple dose	Yes
Safety pharmacology (core)	Relevant species	Single dose	Yes
Safety pharmacology (follow-up)	Relevant species	Multiple dose	Yes

Pharmacokinetics

Study	Species	Design
ADME	Relevant species	IV, SC, PO
PK/PD	Relevant species	Dose-response
Tissue distribution	Relevant species	Radiolabeled
Metabolism	Hepatocytes, microsomes	In vitro

Toxicology

Study	Species	Duration	GLP
Single-dose toxicity	2 species (rodent, non-rodent)	Single dose	Yes
Repeat-dose toxicity	2 species (rodent, non-rodent)	14–28 days (minimum)	Yes
Genotoxicity	Battery	Per ICH S2	Yes
Carcinogenicity	Rodent (if indicated)	2 years	Yes
Reproductive toxicity	2 species	Per ICH S5	Yes
Local tolerance	Relevant species	Single/multiple dose	Yes

Immunogenicity

Study	Method	Purpose
Anti-drug antibody (ADA)	ELISA, bridging assay	Immunogenicity assessment
Neutralizing antibody (NAb)	Cell-based assay	Functional impact
T-cell epitope prediction	In silico	Risk assessment

Clinical Requirements

Phase I

Study	Objective	Design
SAD/MAD	Safety, tolerability, PK	Dose escalation, healthy volunteers or patients
Food effect	PK with/without food	Crossover
Drug-drug interaction	PK interactions	Crossover

Phase II

Study	Objective	Design
Dose-ranging	Efficacy dose finding	Randomized, controlled
PK/PD	Exposure-response	Multiple doses

Phase III

Study	Objective	Design
Efficacy	Primary efficacy endpoint	Randomized, controlled, double-blind
Safety	Long-term safety	Open-label extension

Post-Marketing

Requirement	Timing	Contents
Annual Report	Annual	CMC updates, safety updates
DSUR	Annual	Development safety update
PSUR/PBRER	Periodic	Periodic safety report
Post-marketing study	As committed	IVRS study
Pharmacovigilance	Ongoing	Safety monitoring

References

• Peptide Regulatory Pathways
• Peptide GMP Manufacturing
• Peptide ICH Guidelines
• Peptide Clinical Trials
• FDA-Approved Peptides